Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES P HUDSON

Allopathic & Osteopathic Physicians Dermatology

NPI
1356393102
CMS profile
60996
Location
EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$52,624.55

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES P HUDSON

NPI 1356393102 · CMS profile ID 60996

Allopathic & Osteopathic Physicians / Dermatology

EVANSVILLE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356393102?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES P HUDSON, NPI 1356393102, CMS profile ID 60996. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356393102?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHARLES P HUDSON, NPI 1356393102, CMS profile ID 60996. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356393102?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHARLES P HUDSON, NPI 1356393102, CMS profile ID 60996, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356393102?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $52,624.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $5.7505/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927847 CMS
EPI Health, LLC $10.4605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660677331 CMS
AbbVie, Inc. $17.8905/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927885 CMS
AbbVie, Inc. $156.2105/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927887 CMS
AbbVie, Inc. $3,200.0005/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927931 CMS
AbbVie, Inc. $16.4105/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927949 CMS
AbbVie, Inc. $11.0205/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927951 CMS
AbbVie, Inc. $14.0005/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927953 CMS
AbbVie, Inc. $2,800.0005/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927881 CMS
AbbVie, Inc. $81.1705/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927929 CMS
Novartis Pharmaceuticals Corporation $21.0205/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659573833 CMS
AbbVie, Inc. $2,800.0005/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927883 CMS
DERMIRA, INC. $101.1905/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703883207 CMS
Janssen Biotech, Inc. $2.8405/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658490411 CMS
AbbVie, Inc. $14.4705/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927889 CMS
AbbVie, Inc. $60.2505/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927893 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $12.6305/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684584095 CMS
AbbVie, Inc. $45.0005/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927935 CMS
AbbVie, Inc. $27.6205/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927937 CMS
AbbVie, Inc. $64.1105/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927939 CMS
AbbVie, Inc. $27.6105/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927941 CMS
AbbVie, Inc. $7.2905/03/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927945 CMS
AbbVie, Inc. $483.0005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927947 CMS
AbbVie, Inc. $265.0705/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927933 CMS
AbbVie, Inc. $125.0005/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927943 CMS
Merz North America, Inc. $114.7404/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689366563 CMS
AbbVie, Inc. $1,200.0004/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927877 CMS
AbbVie, Inc. $28.1204/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927871 CMS
AbbVie, Inc. $196.3104/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927873 CMS
AbbVie, Inc. $185.3704/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927875 CMS
AbbVie, Inc. $97.0204/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927997 CMS
AbbVie, Inc. $9.5504/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927999 CMS
AbbVie, Inc. $165.4504/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647928001 CMS
Janssen Scientific Affairs, LLC $69.3304/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657595803 CMS
PruGen, Inc. Pharmaceuticals $7.4704/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707759475 CMS
EPI Health, LLC $22.4504/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660677329 CMS
AbbVie, Inc. $2,800.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927991 CMS
LEO Pharma Inc. $13.1804/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687262425 CMS
AbbVie, Inc. $7.7303/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927879 CMS
AbbVie, Inc. $1,200.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927869 CMS
AbbVie, Inc. $2,800.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927985 CMS
AbbVie, Inc. $2,800.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927989 CMS
AbbVie, Inc. $122.7703/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927995 CMS
AbbVie, Inc. $534.2903/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927981 CMS
AbbVie, Inc. $16.8703/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927983 CMS
AbbVie, Inc. $72.9803/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927987 CMS
AbbVie, Inc. $298.6603/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927993 CMS
AbbVie, Inc. $1,200.0003/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927865 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.3503/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684584093 CMS
AbbVie, Inc. $2,800.0003/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647927863 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $52,624.55 120
PY2020 $26,670.52 66
PY2021 $10,518.76 49
PY2022 $765.71 26
PY2023 $590.71 12
PY2024 $254.63 4
PY2025 $198.29 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $22,498.92 179
PY2023 Principal investigator $93,629.22 128
PY2022 Principal investigator $19,966.87 16
PY2021 Principal investigator $36,555.63 11
PY2020 Recipient $21.90 1
PY2020 Principal investigator $56,834.23 14
PY2019 Recipient $4,447.33 2
PY2019 Principal investigator $267,759.06 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

179 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907035
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907040
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907044
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907048
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907053
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907057
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907061
Principal investigator 1 Dermavant Sciences, Inc. $149.56 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907069
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907074
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907078
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907082
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907087
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907091
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907095
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907100
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907104
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907108
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907117
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907121
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907125
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907129
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907134
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907138
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907142
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907147
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907151
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907155
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907163
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907168
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907172
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907176
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907180
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907185
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907189
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907193
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907197
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907202
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907210
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907214
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907219
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907223
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907227
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907231
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907236
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907240
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907244
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907248
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907257
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907261
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907265
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907270
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907274
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907278
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907282
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907287
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907291
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907295
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907304
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907308
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907312
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907316
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907321
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907325
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907329
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907334
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907338
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907342
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907351
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907355
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907359
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907363
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907367
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907371
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907375
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907380
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907384
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907388
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907396
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907401
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907405
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907409
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907413
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907417
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907421
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127907426
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932502
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932506
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932510
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932515
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932519
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932523
Principal investigator 1 Dermavant Sciences, Inc. $24.75 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932527
Principal investigator 1 Dermavant Sciences, Inc. $149.56 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932536
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932540
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932544
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932548
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932552
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932556
Principal investigator 1 Dermavant Sciences, Inc. $108.64 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932561
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932565
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932569
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932573
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932582
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932586
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932591
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932595
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932599
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932603
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932608
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932612
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932616
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932620
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932628
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932632
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932637
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932641
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932645
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932649
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932653
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932658
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932662
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932666
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932675
Principal investigator 1 Dermavant Sciences, Inc. $116.43 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932679
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932683
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932688
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932692
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932696
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932701
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932705
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932709
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932713
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932722
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932726
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932730
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932734
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932739
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932743
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932747
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932751
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932755
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932760
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932768
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932772
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932776
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932781
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932785
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932789
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932794
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932798
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932802
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932806
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932815
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932819
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932824
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932828
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932832
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932836
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932840
Principal investigator 1 Dermavant Sciences, Inc. $136.23 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932844
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932849
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932853
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932861
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932865
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932869
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932873
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932877
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932881
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932886
Principal investigator 1 Dermavant Sciences, Inc. $114.45 08/03/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127932890
Principal investigator 1 Dermavant Sciences, Inc. $1,500.00 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877857
Principal investigator 1 Dermavant Sciences, Inc. $79.20 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877861
Principal investigator 1 Dermavant Sciences, Inc. $79.20 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877866
Principal investigator 1 Dermavant Sciences, Inc. $79.20 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877870
Principal investigator 1 Dermavant Sciences, Inc. $79.20 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877874
Principal investigator 1 Dermavant Sciences, Inc. $79.20 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877878
Principal investigator 1 Dermavant Sciences, Inc. $100.32 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877883
Principal investigator 1 Dermavant Sciences, Inc. $100.32 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877887
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 06/15/2024 Non-covered Recipient Entity
QUALMEDICA RESEARCH LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127877891